In a study involving 97 patients with advanced, treatment-resistant multiple myeloma, a third responded remarkably to a last-resort immunotherapy developed by Legend Biotech (LEGN). Their cancer disappeared and has not returned after five years — an unprecedented outcome in this incurable disease — and the results have prompted some oncologists to cautiously suggest the possibility of a “potential cure,” The New York Times’ Gina Kolata reports. The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson (JNJ), which has an exclusive licensing agreement with Legend Biotech. Shares of Legend Biotech are up 4.4% to $29.68 in early trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Reveals 5-Year Survival Data for CARVYKTI® at ASCO 2025
- Legend Biotech unveils five-year survival data fro CARVYKTI
- Buy Rating for Legend Biotech Driven by Carvykti’s Market Position and Efficacy
- Legend Biotech’s Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity
- Legend Biotech Unveils Promising CAR-T Therapy Data at ASCO and EHA